Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
33
datasets available to search
ShareScore release 0.9.0
Dataset results
33 results for “Sialic acid”
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
ClinicalTrials.gov study NCT02377921. IPD Sharing: Not stated. Countries: 7. Publications: 2.
The Relationship Between Total Sialic Acid and Superoxide Dismutase and the Diagnosis and Prognosis of Lipoid Pneumonia
ClinicalTrials.gov study NCT06430008. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from: A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
Objective: To investigate the efficacy and safety of aceneuramic acid extended-release (Ace-ER), a treatment intended to replace deficient sialic acid, in patients with GNE myopathy. Methods: UX001-CL301 was a Phase 3, double-blind, placebo-controlled, randomized, international study evaluating the efficacy and safety of Ace-ER in patients with GNE Myopathy. Participants who could walk ≥200 meters in a 6-minute walk test at screening were randomized 1:1, and stratified by sex, to receive Ace-ER 6g/day or placebo for 48 weeks and assessed every 8 weeks. The primary endpoint was change in muscle strength over 48 weeks measured by Upper Extremity Composite (UEC) score. Key secondary endpoints included change in Lower Extremity Composite (LEC) score, knee extensor strength, and GNE myopathy-Functional Activity Scale (GNEM-FAS) mobility domain score. Safety assessments included adverse events (AEs), vital signs, and clinical laboratory results. Results: Eighty-nine patients were randomized (Ace-ER n = 45; Placebo n = 44). Change from baseline to week 48 for UEC score between treatments did not differ (least square mean [LSM] Ace-ER -2.25 kg vs Placebo -2.99 kg; LSM difference (confidence interval [CI]) 0.74 (-1.61, 3.09); p = 0.5387). At week 48, there was no significant difference between treatments for the change in key secondary endpoints: LEC LSM difference (CI) -1.49 (-5.83, 2.86); knee extension strength -0.40 (-2.38, 1.58); and GNEM-FAS mobility domain score -0.72 (-2.01, 0.57). Gastrointestinal events were the most common AEs. Conclusions: Ace-ER was not superior to placebo in improving muscle strength and function in patients with GNE myopathy.
An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epime
ClinicalTrials.gov study NCT01830972. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Data from: A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
Open the record for dataset details and reuse information.
Transcriptional Profiling of Human Placentas from Pregnancies Complicated by Preeclampsia Reveals Disregulation of Sialic Acid Acetylesterase and Immune Signaling Pathways
GEO Series GSE25906. Homo sapiens. 60 samples. Type: Expression profiling by array.
The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma
GEO Series GSE212616. Mus musculus. 7 samples. Type: Expression profiling by high throughput sequencing.
Neuroprotective role of sialic-acid-binding immunoglobulin-like lectin-11 in humanized transgenic mice
GEO Series GSE282391. Mus musculus. 17 samples. Type: Expression profiling by high throughput sequencing.
Impact of nanR delation on the transcriptome of Streptococcus pneumoniae D39 in the presence of sialic acid
GEO Series GSE66535. Streptococcus pneumoniae D39. 2 samples. Type: Expression profiling by array.
Metabolism of sialic acid by Bifidobacterium breve UCC2003
GEO Series GSE56291. Bifidobacterium breve UCC2003. 2 samples. Type: Expression profiling by array.
RNA-seq approaches to understand the biological effects of sialic acid on murine synovial fibroblasts
GEO Series GSE196898. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Transcriptional response of Streptococcus pneumoniae D39 to sialic acid
GEO Series GSE66560. Streptococcus pneumoniae D39. 2 samples. Type: Expression profiling by array.
Mitochondrial dysfunction enhances influenza pathogenesis by upregulating sialic acid biosynthesis
GEO Series GSE281057. Mus musculus. 29 samples. Type: Expression profiling by high throughput sequencing.
Next-generation sequencing of human monocyte-derived dendritic cells stimulated with sialic acid glycodendrimers in the absence or presence of LPS
GEO Series GSE168887. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.
Impact of ccpA delation on the transcriptome of Streptococcus pneumoniae D39 in the presence of sialic acid
GEO Series GSE66559. Streptococcus pneumoniae D39. 2 samples. Type: Expression profiling by array.
Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone
GEO Series GSE236208. Homo sapiens. 11 samples. Type: Expression profiling by high throughput sequencing.
Transcriptional regulation of the sialic acid utilization gene cluster of Bifidobacterium breve UCC2003 by a GntR-type transcriptional repressor.
GEO Series GSE62885. Bifidobacterium breve UCC2003. 2 samples. Type: Expression profiling by array.
An RNase III-processed sRNA coordinates sialic acid metabolism of Salmonella enterica during gut colonization
GEO Series GSE269329. Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344. 10 samples. Type: Expression profiling by high throughput sequencing.
Sialic acid-mediated gene expression in Streptococcus pneumoniae and the role of NanR as a transcriptional activator of the nan gene cluster
GEO Series GSE66561. Streptococcus pneumoniae D39. 8 samples. Type: Expression profiling by array.
Estimation of Sialic Acid and IL10 Levels in Stage 1 and 2 Periodontitis Patients
ClinicalTrials.gov study NCT03775967. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.